Humanized antibody for resisting neocoronavirus S protein and application thereof

• Main Authors: XIAO HANG, CHENG HAO, XIAN JIAHUAN, WU QIHUI, LOU YANG, LIU YANG, TABAI HIDEKO, WANG PEIRONG
• Format: Patent
• Language: Chinese; English
• Published: 14.07.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The invention belongs to the technical field of preparation of humanized antibodies, and particularly relates to an anti-neocoronavirus S protein humanized antibody and application thereof. A complementarity determining region of the humanized antibody for resisting the new coronavirus S protein is derived from a rabbit-derived monoclonal antibody 1H1, and a framework region of the humanized antibody is derived from a human antibody; the amino acid sequences of the light chain framework region 1, the light chain framework region 2, the light chain framework region 3 and the light chain framework region 4 are respectively as shown in SEQ ID NO: 11-14; the amino acid sequences of the heavy chain framework region 1, the heavy chain framework region 2, the heavy chain framework region 3 and the heavy chain framework region 4 are respectively as shown in SEQ ID NO: 15-18. According to the present invention, the frame region of the rabbit source monoclonal antibody 1H1 is modified, such that the immunogenicity of t